MicroRNAs and epithelial mesenchymal transition in cancer

Abstract

HAN Xue, LI Man. MicroRNAs and epithelial mesenchymal transition in cancer[J]. Journal of International Oncology, 2014, 41(12): 881-884.

［1］ Sreekumar R, Sayan BS, Mirnezami AH, et al. MicroRNA control of invasion and metastasis pathways［J］. Front Genet, 2011(2): 58．［2］ Johansson J, Berg T, Kurzejamska E, et al. MiR155mediated loss of C/EBPβ shifts the TGFβ response from growth inhibition to epithelialmesenchymal transition, invasion and metastasis in breast cancer［J］. Oncogene, 2013, 32(50): 56145624. ［3］ Stinson S, Lackner MR, Adai AT, et al. TRPS1 targeting by miR 221/222 promotes the epithelialtomesenchymal transition in breast cancer［J］. Sci Signal, 2011, 4(177): ra41. ［4］ Hwang MS, Yu N, Stinson SY, et al. MiR221/222 targets adiponectin receptor 1 to promote the epithelialmesenchymal transition in breast cancer［J］. PLoS One, 2013, 8(6): e66502. ［5］ Arora H, Qureshi R, Park WY. MiR506 regulates epithelial mesenchymal transition in breast cancer cell lines［J］. PLoS One, 2013, 8(5): 64273. ［6］ Hamada S, Satoh K, Fujibuchi W, et al. MiR126 acts as a tumor sppressor in pancreatic cancer cells via the regulation of ADAM9［J］. Mol Cancer Res, 2012, 10(1): 310. ［7］ Harazono Y, Muramatsu T, Endo H, et al. miR655 is an EMTsuppressive microRNA targeting ZEB1 and TGFBR2［J］. PLoS One, 2013, 8(5): 62757. ［8］ Zheng H, Li W, Wang Y, et al. miR23a inhibits Ecadherin expression and is regulated by AP1 and NFAT4 complex during Fasinduced EMT in gastrointestinalcancer［J］. Carcinogenesis, 2014, 35(1): 173183. ［9］ Hamada S, Satoh K, Miura S, et al. miR197 induces epithelial mesenchymal transition in pancreatic cancer cells by targeting p120 catenin［J］. J Cell Physiol, 2013, 228(6): 12551263. ［10］ Guo S, Xu X, Tang Y, et al. miR15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by downregulating Bmi1 expression［J］. Cancer Lett, 2014, 344(1): 4046. ［11］ Cai ZG, Zhang SM, Zhang H, et al. Aberrant expression of microRNAs involved in epithelialmesenchymal transition of HT29 cell line［J］. Cell Biol Int, 2013, 37(7): 669674. ［12］ Shi L, Jackstadt R, Siemens H, et al. p53induced miR15a/161 and AP4 form a doublenegative feedback loop to regulate epithelialmesenchymal transition and metastasis in colorectal cancer［J］. Cancer Res, 2014, 74(2): 532542. ［13］ Wang SH, Li X, Zhou LS, et al. microRNA148a suppresses human gastric cancer cell metastasis by reversing epithelialtomesenchymal transition［J］. Tumour Biol, 2013, 34(6): 37053712. ［14］ Zhang L, Wang X, Chen P. miR204 down regulates SIRT1 and reverts SIRT1induced epithelialmesenchymal transition, anoikis resistance and invasion in gastric cancer cells［J］. BMC Cancer, 2013, 13: 290. ［15］ Zhou Y, Li Y, Ye J, et al. MicroRNA491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition［J］. Live Int, 2013, 33(8): 12711280. ［16］ Xia H, Ooi LL, Hui KM. MicroRNA216a/217induced epithelial mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer［J］. Hepatology, 2013, 58(2): 629641. ［17］ Chiou GY, Cherng JY, Hsu HS, et al. Cationic polyurethanes short branch PEImediated delivery of Mir145 inhibited epithelialmesenchymal transdiferentiation and can cer stem like properties and in lung adenocarcinoma［J］. J Control Release, 2012, 159(2): 240250．［18］ Zhu C, Li J, Cheng G, et al. MiR154 inhibits EMT by targeting HMGA2 in prostate cancer cells［J］. Mol Cell Biochem, 2013, 379(12): 6975. ［19］ Qu Y, Li WC, Hellem MR, et al. MiR182 and miR203 induce mesenchymal to epithelial transition and selfsufficiency of growth signals via repressing SNAI2 in prostate cells［J］. Int J Cancer, 2013, 133(3): 544555. ［20］ Joglekar MV, Patil D, Joqlekar VM, et al. The miR30 family miRNAs confer epithe1ia1 phenotype to human pancreatic cells［J］. Islets, 2009, 1(2): l37147. ［21］ Kumarswamy R, Mudduluru G, Ceppi P, et al. MicroRNA30a inhibits epithelialto mesenehymal transition by targeting Snail and is downregulated in non small cell lung cancer［J］. Int J Cancer, 2012, 130(9): 20442053．［22］ Huang J, Yao X, Zhang J, et al. Hypoxiainduced downregulation of miR30c promotes epithelialmesenchymal transition in human renal cell carcinoma［J］. Cancer Sci, 2013, 104(12): 16091617. ［23］ Chen J, Li Q, An Y, et al. CEACAM6 induces epithelialmesenchymal transition and mediates invasion and metastasis in pancreatic cancer［J］. Int J Oncol, 2013, 43(3): 877885. ［24］ Gebeshuber CA, Zatloukal K, Martinez J． MiR29a suppresses tristetraprohn, which is a regulator of epithelial polarity and metastasis［J］． EMBO Rep, 2009, 10(4): 400405．［25］ Ru P, Steele R, Newhall P, et al． miRNA29b suppresses prostate cancer metastasis by regulating epithelialmesenchymal transition signaling［J］． Mol Cancer Ther, 2012, 11(5): 11661173. ［26］ Colangelo T, Fucci A, Votino C, et al. MicroRNA130b promotes tumor development and is associated with poor prognosis in colorectal cancer［J］. Neoplasia, 2013, 15(9): 10861099. ［27］ Dong P, Karaayvaz M, Jia N, et al. Mutant p53 gainoffunction induces epithelial mesenchymal transition through modulation of the miR130bZEB1 axis［J］. Oncogene, 2013, 32(27): 32863295.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

MicroRNAs and epithelial mesenchymal transition in cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments